Retatrutide Explained: Triple Agonist Research (Philippines Guide)

Name: Retatrutide Explained: Triple Agonist Research (Philippines Guide)
Uploaded: 2026-10-01T09:00:00+08:00
Duration: 1 min 50 s
Description: Retatrutide explained in 90 seconds: how the GIP, GLP-1 and glucagon triple agonist works, what the phase 2 and phase 3 trials found, and its approval status. Research notes

Retatrutide explained in 90 seconds: how the GIP, GLP-1 and glucagon triple agonist works, what the phase 2 and phase 3 trials found, and its approval status. Research notes

Transcript

One molecule, three hormone receptors. Could that be the next step in obesity research? This is retatrutide, an investigational peptide that researchers call a triple agonist. It activates three receptors: GIP, GLP-1, and glucagon.

Think of it as one key that fits three locks. GIP and GLP-1 are gut hormones linked to appetite and blood sugar. The glucagon receptor is being studied for how the body uses energy. So what does the research show?

In a 2023 phase 2 trial in the New England Journal of Medicine, 338 adults with obesity or overweight were followed for 48 weeks. At the highest dose tested, average weight loss was 24.2 percent. In May 2026, the phase 3 trial TRIUMPH-1 reported results in 2,339 adults without diabetes.

At 80 weeks, the highest dose group lost 28.3 percent of body weight on average, versus 2.2 percent on placebo. The most common side effects were nausea, diarrhea and constipation, and they rose with dose.

At the highest dose, 11.3 percent stopped because of side effects, versus 4.9 percent on placebo. Long-term safety is still being studied.

Status: retatrutide is not approved anywhere yet. Its developer plans to file with the US FDA in early 2027. Research-grade vials are not approved medicines. If you are sourcing research peptides in the Philippines, Primara Labs publishes independent lab reports you can verify yourself.

Guides at primaralabs.com.